Percheron Therapeutics

Quarterly update

HMBD-002 Phase II preparations remain on track

Pharma and biotech

4 August 2026

Percheron Therapeutics' update for the quarter to 30 June confirmed that Phase II preparations for HMBD-002 (provisional name: minperstobart) remain on track. GMP drug substance manufacture is complete and final drug product is expected to be released in September 2026, supporting our Q4 CY26 Phase II initiation assumption. The A$2.2m entitlement offer lifted the end-Q2 CY26 cash to A$4.05m (end-Q1 CY26: A$3.10m), modestly ahead of our A$3.8m estimate. Quarterly operating cash burn was A$1.05m, including R&D expenses of A$0.43m. While the company reports a 3.9-quarter runway based on the pre-trial expenditure rate, this excludes the remaining US$1m (c A$1.4m) licence payment to Hummingbird Bioscience and the expected increase in spending once Phase II begins. We therefore continue to estimate funding into Q1 CY27, sufficient to initiate the trial, but with additional capital required to advance and complete the study. With no material change to our assumptions, we retain our A$84.4m, or 5.5c per share, valuation. We expect the September drug-product release and Q4 CY26 trial initiation to be the key upcoming catalysts.

Year end	Revenue (AUDm)	PBT (AUDm)	EPS (AUD)	DPS (AUc)	P/E (x)	Yield (%)
6/24	2.4	(11.7)	(1.33)	0.00	N/A	N/A
6/25	1.4	(13.4)	(1.31)	0.00	N/A	N/A
6/26e	0.0	(5.8)	(0.38)	0.00	N/A	N/A
6/27e	0.9	(7.2)	(0.47)	0.00	N/A	N/A

Note: PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Percheron's quarterly activities report highlighted continued operational progress ahead of the planned start of the Phase II study. Completion of drug substance manufacture in June 2026 by Hummingbird (under the 2025 licence) removes a key manufacturing risk and Percheron will now undertake fill-and-finish activities, with final drug product expected to br released in September. This is consistent with previously communicated timelines and supports our assumption of Phase II initiation in Q4 CY26. Importantly, future manufacturing responsibility transfers to Percheron, so successful delivery of this final step would demonstrate growing operational ownership as the programme enters mid-stage development.

The report recapped data presented at the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). At AACR, Phase I analyses had supported a 720mg once-weekly Phase II dose, and the ASCO preclinical data showed that VISTA expression increased following chemotherapy and PD-1/PD-L1 blockade. This strengthens our expectation that triple-negative breast cancer will be prioritised in the adaptive basket study.

Supported by the A$2.2m raise in April 2026, Percheron exited the quarter with a net cash balance of A$4.05m (slightly ahead of our A$3.8m estimate). The reported 3.9-quarter runway is based on the pre-trial expenditure rate, and we believe this does not reflect the remaining US$1m (c A$1.4m) upfront licence payment to Hummingbird, which we model in July 2026, or the anticipated increase in spending following Phase II initiation. We therefore continue to estimate a cash runway into Q1 CY27. This makes capital availability and potential partnering important sensitivities. Nevertheless, timely Phase II initiation would represent a meaningful near-term inflection point and could support a re-rating. With the update broadly in line with our expectations, we maintain our valuation of A$84.4m, or 5.5c per share.

Price	**AUD0.003**
Market cap	**AUD5m**
	US$/A$1.43
Net cash/(debt) at 30 June 2026	AUD4.1m
Shares in issue	1,522.4m
Free float	56.0%
Code	PER
Primary exchange	ASX
Secondary exchange	N/A

Share price performance



Business description

Percheron Therapeutics is a clinical-stage biotech advancing HMBD-002, a differentiated VISTA-targeting checkpoint inhibitor with potential to address PD-1 resistance across a range of cancer indications. HMBD-002 has completed a Phase I clinical trial in patients with advanced cancer, with favourable safety and tolerability. The Phase II trial is expected to commence in Q4 CY26.

Analysts

Jyoti Prakash, CFA +44 (0)20 3077 5700
Arron Aatkar, PhD +44 (0)20 3077 5700

healthcare@edisongroup.com
Edison profile page

General disclaimer and copyright

This report has been commissioned by Percheron Therapeutics and prepared and issued by Edison, in consideration of a fee payable by Percheron Therapeutics. Edison Investment Research standard fees are £60,000 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Australia

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

New Zealand

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

United Kingdom

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or sol icitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment activity to which this document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on or act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

United States

Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security in this report constitutes a recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.

London | New York | Frankfurt
20 Red Lion Street
London, WC1R 4PS
United Kingdom